Keyword: Keytruda

BMS has been waiting years to get a crack at the previously untreated NSCLC market, but the end to its waiting may finally be in sight.

Only weeks ago, Merck's I-O superstar Keytruda whiffed in a key lung cancer trial. Now the therapy is facing pushback from England's cost watchdog.

Approvals in metastatic bladder cancer in hand, Keytruda has become the first PD-1/L1 to win an FDA nod in non-muscle invasive bladder cancer.

While a Keytruda-chemo combo showed significant improvement in cutting disease worsening or death in SCLC, it didn't extend patients' lives.

An FDA advisory panel voted 9-4 in favor of approving Keytruda for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer.

Roche has faced criticism that the diagnostic used to ID trial patients might have swayed Tecentriq's lung cancer results. Not so, an analysis says.

Merck & Co. set out to answer the question of whether lung cancer patients with KRAS mutations respond as well to Keytruda as others do.

Merck and Roche are no strangers to sparring with their I-O meds Keytruda and Tecentriq, but in TNBC, Keytruda's latest data take the prize.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.